Medical device software (SaMD) development requires the intersection of clinical understanding, regulatory expertise, and rigorous software engineering — IEC 62304 compliant development, FDA 510(k) documentation, risk management per ISO 14971, and cybersecurity by design. Scale D2C builds medical device software to the standards that get products to market and keep patients safe.
Scale D2C's Medical Device Software Development service covers strategy, implementation, integration with your DTC tech stack, and ongoing optimisation. Our team has delivered Medical Device Software Development for DTC and ecommerce brands across beauty, health, fashion, and B2B — from Series A startups through to publicly listed companies.
Medical Device Software Development impacts DTC revenue by improving operational efficiency, customer experience, or marketing performance. Scale D2C defines clear, agreed KPIs — revenue uplift, cost reduction, or conversion improvement — before every Medical Device Software Development engagement, so success is never ambiguous.
Focused Medical Device Software Development implementations typically take 8–12 weeks. Projects with multiple integrations or data complexity run 16–24 weeks. Scale D2C provides a detailed project plan with milestone dates at the end of the discovery phase — no timeline surprises mid-project.
Scale D2C structures Medical Device Software Development content and pages with AEO and GEO best practices — FAQ schema, structured data, entity markup, and topical authority content — so your brand is cited in AI-generated answers on ChatGPT, Perplexity, Google Gemini, Claude, Deepseek, and Sarvam AI.
Scale D2C brings DTC commercial expertise and deep Medical Device Software Development technical capability together. Unlike generalist agencies, we understand how Medical Device Software Development fits into a DTC growth strategy — every decision is made with your revenue goals in mind, not just technical delivery metrics.
Medical device software failures have real patient consequences. Regulated development isn't overhead — it's the product.